Insider · CIK 0001587800
Kevin M. Lalande
Files at LUMOS PHARMA, INC., MTEM (Molecular Templates, Inc.). First filing -, latest -.
In brief
Kevin M. Lalande files SEC Form 4 as director and 10% owner at LUMOS PHARMA, INC., and also at MTEM (Molecular Templates, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Kevin M. Lalande has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Common Stock | -1,076 | - | - | 0 | Dec 13, 2024 |
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Common Stockindirect: By Sante Health Ventures II, LP | -730,446 | - | - | 0 | Dec 13, 2024 |
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,345 | - | - | 0 | Dec 13, 2024 |
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,328 | - | - | 0 | Dec 13, 2024 |
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,684 | - | - | 0 | Dec 13, 2024 |
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,431 | - | - | 0 | Dec 13, 2024 |
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -2,910 | - | - | 0 | Dec 13, 2024 |
| Oct 27, 2023 | MTEM Molecular Templates, Inc. | AGrant or award Stock Option (right to buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Oct 31, 2023 |
Questions about Kevin M. Lalande
Answered from the filings on this page, as of the latest one.
Is Kevin M. Lalande buying or selling?
Kevin M. Lalande has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Kevin M. Lalande's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kevin M. Lalande has 0.
Where does Kevin M. Lalande file Form 4?
Kevin M. Lalande has filed Form 4 at LUMOS PHARMA, INC.; MTEM (Molecular Templates, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.